Trial Profile
Efficacy and safety of apatinib in the treatment of recurrent or metastatic cervical cancer patients
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Jun 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
- 21 Jun 2018 New trial record